| Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma I Janoueix-Lerosey, D Lequin, L Brugières, A Ribeiro, L De Pontual, ... Nature 455 (7215), 967-970, 2008 | 1035 | 2008 |
| ALK-positive lymphoma: a single disease with a broad spectrum of morphology D Benharroch, Z Meguerian-Bedoyan, L Lamant, C Amin, L Brugières, ... Blood, The Journal of the American Society of Hematology 91 (6), 2076-2084, 1998 | 653 | 1998 |
| Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers G Bougeard, M Renaux-Petel, JM Flaman, C Charbonnier, P Fermey, ... Journal of Clinical Oncology 33 (21), 2345-2352, 2015 | 647 | 2015 |
| A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma C Bertolotto, F Lesueur, S Giuliano, T Strub, M De Lichy, K Bille, P Dessen, ... Nature 480 (7375), 94-98, 2011 | 596 | 2011 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 523 | 2018 |
| Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer S Cairo, C Armengol, A De Reyniès, Y Wei, E Thomas, CA Renard, ... Cancer cell 14 (6), 471-484, 2008 | 520 | 2008 |
| P53 germline mutations in childhood cancers and cancer risk for carrier individuals A Chompret, L Brugières, M Ronsin, M Gardes, F Dessarps-Freichey, ... British journal of cancer 82 (12), 1932-1937, 2000 | 474 | 2000 |
| Cancer screening recommendations for individuals with Li-Fraumeni syndrome CP Kratz, MI Achatz, L Brugieres, T Frebourg, JE Garber, MLC Greer, ... Clinical Cancer Research 23 (11), e38-e45, 2017 | 456 | 2017 |
| Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium ‘care for CMMRD’(C4CMMRD) K Wimmer, CP Kratz, HFA Vasen, O Caron, C Colas, N Entz-Werle, ... Journal of medical genetics 51 (6), 355-365, 2014 | 432 | 2014 |
| Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study J Zsíros, R Maibach, E Shafford, L Brugieres, P Brock, P Czauderna, ... J Clin Oncol 28 (15), 2584-2590, 2010 | 360 | 2010 |
| Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort SM Waszak, PA Northcott, I Buchhalter, GW Robinson, C Sutter, ... The Lancet Oncology 19 (6), 785-798, 2018 | 352 | 2018 |
| Sensitivity and predictive value of criteria for p53germline mutation screening A Chompret, A Abel, D Stoppa-Lyonnet, L Brugieres, S PAGÈS, ... Journal of medical genetics 38 (1), 43-47, 2001 | 347 | 2001 |
| Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma G Perilongo, R Maibach, E Shafford, L Brugieres, P Brock, B Morland, ... New England Journal of Medicine 361 (17), 1662-1670, 2009 | 344 | 2009 |
| Risk-adapted treatment for childhood hepatoblastoma: Final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2 G Perilongo, E Shafford, R Maibach, D Aronson, L Brugieres, P Brock, ... European Journal of Cancer 40 (3), 411-421, 2004 | 344 | 2004 |
| CD30+ Anaplastic Large-Cell Lymphoma in Children: Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology L Brugieres, MCL Deley, H Pacquement, Z Meguerian-Bedoyan, ... Blood, The Journal of the American Society of Hematology 92 (10), 3591-3598, 1998 | 332 | 1998 |
| Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study J Zsiros, L Brugieres, P Brock, D Roebuck, R Maibach, A Zimmermann, ... The lancet oncology 14 (9), 834-842, 2013 | 313 | 2013 |
| BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy S Héritier, JF Emile, MA Barkaoui, C Thomas, S Fraitag, S Boudjemaa, ... Journal of clinical oncology 34 (25), 3023, 2016 | 303 | 2016 |
| Sodium thiosulfate for protection from cisplatin-induced hearing loss PR Brock, R Maibach, M Childs, K Rajput, D Roebuck, MJ Sullivan, ... New England Journal of Medicine 378 (25), 2376-2385, 2018 | 277 | 2018 |
| High incidence of the t (2; 5)(p23; q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis … L Lamant, F Meggetto, T Al Saati, L Brugieres, BB de Paillerets, ... | 270 | 1996 |
| Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead V Minard-Colin, L Brugières, A Reiter, MS Cairo, TG Gross, ... Journal of Clinical Oncology 33 (27), 2963, 2015 | 268 | 2015 |
